Bausch Health Companies Inc.BHCEarnings & Financial Report
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
BHC Q4 FY2025 Key Financial Metrics
Revenue
$2.8B
Gross Profit
N/A
Operating Profit
$474.0M
Net Profit
$-103.0M
Gross Margin
N/A
Operating Margin
17.0%
Net Margin
-3.7%
YoY Growth
9.3%
EPS
$-0.30
Bausch Health Companies Inc. Q4 FY2025 Financial Summary
Bausch Health Companies Inc. reported revenue of $2.8B (up 9.3% YoY) for Q4 FY2025, with a net profit of $-103.0M (down 205.1% YoY) (-3.7% margin).
Key Financial Metrics
| Total Revenue | $2.8B |
|---|---|
| Net Profit | $-103.0M |
| Gross Margin | N/A |
| Operating Margin | 17.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Bausch Health Companies Inc. Q4 FY2025 revenue of $2.8B breaks down across 5 segments, led by Bausch Lomb at $1.4B (50.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Bausch Lomb | $1.4B | 50.3% |
| Salix Segment | $693.0M | 24.8% |
| International Rx | $306.0M | 10.9% |
| Diversified Segment | $255.0M | 9.1% |
| Solta Medical Segment | $137.0M | 4.9% |
Bausch Health Companies Inc. Revenue by Segment — Quarterly Trend
Bausch Health Companies Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Bausch Lomb and Salix Segment) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Bausch Lomb | $1.4B | $1.3B | — | $1.1B |
| Salix Segment | $693.0M | $716.0M | — | $542.0M |
| International Rx | $306.0M | $286.0M | — | $262.0M |
| Diversified Segment | $255.0M | $258.0M | — | $205.0M |
| Solta Medical Segment | $137.0M | $140.0M | — | $113.0M |
Bausch Health Companies Inc. Annual Revenue by Year
Bausch Health Companies Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.3B).
Bausch Health Companies Inc. Quarterly Revenue & Net Profit History
Bausch Health Companies Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.8B | +9.3% | $-103.0M | -3.7% |
| Q3 FY2025 | $2.7B | +6.8% | $179.0M | 6.7% |
| Q2 FY2025 | $2.5B | +5.3% | $148.0M | 5.8% |
| Q1 FY2025 | $2.3B | +4.9% | $-58.0M | -2.6% |
| Q4 FY2024 | $2.6B | +6.3% | $98.0M | 3.8% |
| Q3 FY2024 | $2.5B | +12.2% | $-85.0M | -3.4% |
| Q2 FY2024 | $2.4B | +10.9% | $10.0M | 0.4% |
| Q1 FY2024 | $2.2B | +10.8% | $-64.0M | -3.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.15B | $2.40B | $2.51B | $2.56B | $2.26B | $2.53B | $2.68B | $2.80B |
| YoY Growth | 10.8% | 10.9% | 12.2% | 6.3% | 4.9% | 5.3% | 6.8% | 9.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.91B | $26.50B | $26.54B | $26.52B | $26.42B | $27.27B | $26.82B | $26.37B |
| Liabilities | $27.09B | $26.72B | $26.78B | $26.84B | $26.66B | $27.12B | $26.47B | $25.99B |
| Equity | $-1.11B | $-1.18B | $-1.17B | $-1.28B | $-1.18B | $-764.0M | $-565.0M | $-554.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $211.0M | $380.0M | $405.0M | $601.0M | $211.0M | $289.0M | $405.0M | $495.0M |